What Actually Reaches Evogene Shareholders: Non-Controlling Interests, Lavie Dividends, and the Biomica Path
Evogene ended 2025 with a narrower structure, but that did not turn group value into parent-level value. Year-end equity attributable to Evogene shareholders was negative $0.082 million while $12.057 million still sat in non-controlling interests, so the real question is not only how much value remains in Lavie and Biomica, but how much actually moves upstream.
Where Value Gets Cut on the Way to Shareholders
The main article already argued that Evogene’s reset cleaned up the operating story: fewer activities, a clearer core engine, and less scattered cash burn. This follow-up isolates the part that is still less clean. The question here is not whether value remains inside Lavie and Biomica. The question is how much of that value actually crosses the subsidiary layer and reaches Evogene’s ordinary shareholders.
The CEO letter presents a company that is more focused, more agile, and more capital-efficient after the Lavie divestment and the BMC128 licensing deal at Biomica. That is directionally true. But once the lens shifts from strategic focus to accessible value, three frictions matter immediately: minority ownership inside the subsidiaries, the need for formal dividend approvals, and the fact that part of the remaining Biomica upside sits in milestones and royalties rather than in cash already held at the parent.
| Layer | Reported figure | Why it matters for Evogene shareholders |
|---|---|---|
| Total equity at year-end 2025 | $11.975 million | This is the consolidated number before splitting value between the parent and minorities |
| Equity attributable to Evogene shareholders | Negative $0.082 million | The parent layer itself finished the year slightly negative |
| Non-controlling interests | $12.057 million | Almost all consolidated equity still sits outside the ordinary-shareholder layer |
| Approved Lavie dividend | $4.25 million | This is the first real proof that sale value is being distributed upstream |
| Amount Evogene already received from Lavie | About $2.928 million in March 2026 | This is cash that has already crossed the subsidiary line |
| Approved Biomica dividend | Up to $2.7 million, subject to court approval | There is an upstream path, but no disclosed cash receipt at the parent yet |
This is the key number: by the end of 2025, total group equity was positive, but equity attributable to Evogene shareholders was still negative. Anyone who reads only the consolidated equity line misses the fact that the parent layer itself had not yet crossed into positive territory.
That chart explains why this continuation matters. The group’s equity is not sitting in the ordinary-shareholder layer. $12.057 million belongs to non-controlling interests, and only after subtracting that amount do we reach the Evogene shareholder line, which is negative.
Even the decline in non-controlling interests during 2025 does not look like a clean story of cash moving upstream. The balance fell from $16.289 million to $12.057 million, but the largest component was a $4.742 million line tied to forfeiture of non-controlling interests regarding share-based compensation. The note also includes a negative $0.086 million share-based compensation item and a negative $0.062 million item tied to exercise of subsidiary options. Against that, $0.658 million of 2025 profit was still attributed to non-controlling interests. This is not a picture of value opening up through broad distributions to the parent. It is mainly a capital-movement story, while the minority layer remains material.
Lavie: Cash Has Started Moving Up, but Not the Entire Story
Lavie is the cleaner part of the picture precisely because the activity itself is already behind the company. As of the annual-report date, no additional Lavie activity was expected, and the company had already distributed and expected to continue distributing most of its remaining cash during 2026 and 2027. That makes Lavie the clearest current path from monetized subsidiary value into the parent’s cash box.
But ownership still matters first. Evogene owns 68.9% of Lavie, while the remaining 31.1% is held by Corteva and former Lavie employees. In practical terms, every Lavie distribution is shared before it ever reaches Evogene’s own shareholders.
The 2025 numbers show why this matters. Income from discontinued operations came to $5.672 million, but only $4.877 million was attributable to Evogene shareholders. Another $0.795 million was attributable to non-controlling interests. So even at the exit line itself, Lavie was no longer a 100%-Evogene economics story.
The real proof of upstream value comes only after year-end. In November 2025, Lavie approved a $4.25 million dividend, subject to court approval. After approval was obtained, Evogene disclosed that it had already received about $2.928 million out of that dividend in March 2026. The absolute number is not huge, but analytically it matters a lot, because it shows that Lavie value is in fact beginning to move up the chain.
The amount Evogene received lines up almost exactly with its ownership stake in Lavie. That is the whole point. The sale of the activity, the accounting gain, and the cash still held at the subsidiary are not the same thing as cash that is already accessible to Evogene shareholders. To become ordinary-shareholder value, the money first has to be distributed, and only then is it allocated according to the actual ownership structure.
Biomica: A Shared and Conditional Path, Still Not Cash
Biomica is more complicated than Lavie because it is not being resolved through a full sale. Instead, it is moving from an internally funded development model into a licensing-and-optionality model. At the report date, Evogene owned 75.8% of Biomica, while the remaining 24.2% was held by SHC and Biomica’s CTO. That means every future distribution and every future milestone stream is shared from the outset between the parent and minority holders.
During 2025, Biomica was sharply scaled down. Two pre-clinical programs were discontinued, headcount was reduced, and by the report date the company employed only 1.5 full-time employees. What remained was the Phase I trial for BMC128, expected to be completed by June 2026, and the exclusive worldwide license agreement with Lishan Biotech signed in February 2026. Under that agreement, Biomica may receive development milestones, sales milestones, and royalties, subject to clinical progress, regulatory approvals, and future product sales.
That is an important improvement in the quality of the story. On one hand, Biomica no longer looks like a platform that still needs broad internal investment. After the completion of Phase I, no further activity is expected, and the annual report frames Biomica as moving from direct burn toward a narrower, more limited economic path. On the other hand, what remains after that is not clean cash. It is contingent economics: the partner has to execute, milestones have to mature, and only then do receipts appear.
There is also a more immediate distribution layer. Biomica expects to distribute most of its remaining cash to its shareholders, including Evogene. On February 25, 2026, Biomica’s board approved a dividend of up to $2.7 million, again subject to court approval, and by the report date a motion had already been filed. Unlike Lavie, however, there is still no disclosure of cash already received at the parent.
That is why Biomica now sits on two very different layers. The first is a possible dividend that has already been approved at the board level but still depends on court approval and had not yet become disclosed cash at Evogene by the report date. The second is future upside under the Lishan Biotech agreement, which sits even farther away from the parent: it depends not only on a third party’s execution, but also remains shared with Biomica’s minority holders.
That is the material difference versus Lavie. At Lavie, there is already proof that cash is moving upstream. At Biomica, there is still mainly a path. It may yet prove valuable, but as of year-end 2025 and the subsequent-event disclosures, it is still not the same thing as cash that is already accessible at the parent.
Conclusion
The bottom line is that Evogene has indeed become more focused, but the value that still sits around its subsidiaries does not fully belong, and is not always directly accessible, to Evogene’s ordinary shareholders. At the end of 2025, the parent equity layer was still negative. At Lavie, cash is already proving that it can move upstream, but only according to Evogene’s ownership share. At Biomica, there is a possible dividend and future upside, but both still sit behind minority holders, court approval, and third-party execution.
Put differently, anyone trying to understand what actually reaches Evogene shareholders has to track three separate steps: how much value remains inside the subsidiaries, how much of it has been approved for distribution, and how much has already arrived in the parent’s cash balance. Until all three steps are completed, the gap between group value and shareholder-accessible value remains material.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.